ES2999323T3 - Tlr8 agonist - Google Patents

Tlr8 agonist Download PDF

Info

Publication number
ES2999323T3
ES2999323T3 ES19862693T ES19862693T ES2999323T3 ES 2999323 T3 ES2999323 T3 ES 2999323T3 ES 19862693 T ES19862693 T ES 19862693T ES 19862693 T ES19862693 T ES 19862693T ES 2999323 T3 ES2999323 T3 ES 2999323T3
Authority
ES
Spain
Prior art keywords
compound
pharmaceutically acceptable
tautomer
stereoisomer
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19862693T
Other languages
English (en)
Spanish (es)
Inventor
Zhe Cai
Fei Sun
Charles Z Ding
Shuhui Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Application granted granted Critical
Publication of ES2999323T3 publication Critical patent/ES2999323T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES19862693T 2018-09-19 2019-09-19 Tlr8 agonist Active ES2999323T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811094969 2018-09-19
PCT/CN2019/106687 WO2020057604A1 (zh) 2018-09-19 2019-09-19 Tlr8激动剂

Publications (1)

Publication Number Publication Date
ES2999323T3 true ES2999323T3 (en) 2025-02-25

Family

ID=69888288

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19862693T Active ES2999323T3 (en) 2018-09-19 2019-09-19 Tlr8 agonist

Country Status (11)

Country Link
US (1) US12054482B2 (https=)
EP (1) EP3854794B1 (https=)
JP (1) JP7498702B2 (https=)
KR (1) KR102856089B1 (https=)
CN (2) CN112805283B (https=)
AU (1) AU2019344868B2 (https=)
CA (1) CA3112953A1 (https=)
ES (1) ES2999323T3 (https=)
PH (1) PH12021550601A1 (https=)
SG (1) SG11202102641RA (https=)
WO (1) WO2020057604A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202102641RA (en) 2018-09-19 2021-04-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Tlr8 agonist
EP4122931B1 (en) * 2020-03-18 2025-07-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystalline form of tlr8 agonist
CN116472047B (zh) * 2021-11-05 2025-06-17 中国医药研究开发中心有限公司 芳胺类衍生物及其制备方法和医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0503506D0 (en) 2005-02-21 2005-03-30 4 Aza Bioscience Nv Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
SG194852A1 (en) 2011-05-18 2013-12-30 Janssen R & D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases
WO2013022766A1 (en) 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
EP2925729B1 (en) 2012-11-16 2017-10-18 Janssen Sciences Ireland UC Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
WO2016141092A1 (en) 2015-03-04 2016-09-09 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
EP3507288B1 (en) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CN109923106B (zh) 2016-09-02 2022-09-13 吉利德科学公司 toll样受体调节剂化合物
SG11202102641RA (en) 2018-09-19 2021-04-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Tlr8 agonist

Also Published As

Publication number Publication date
JP7498702B2 (ja) 2024-06-12
EP3854794A1 (en) 2021-07-28
JP2022501350A (ja) 2022-01-06
AU2019344868A1 (en) 2021-04-15
AU2019344868B2 (en) 2024-06-27
US12054482B2 (en) 2024-08-06
CN112805283A (zh) 2021-05-14
WO2020057604A1 (zh) 2020-03-26
SG11202102641RA (en) 2021-04-29
PH12021550601A1 (en) 2021-11-29
KR102856089B1 (ko) 2025-09-04
CN115650979A (zh) 2023-01-31
KR20210060567A (ko) 2021-05-26
CA3112953A1 (en) 2020-03-26
US20210371414A1 (en) 2021-12-02
EP3854794A4 (en) 2022-06-15
CN112805283B (zh) 2022-09-20
EP3854794B1 (en) 2024-11-27

Similar Documents

Publication Publication Date Title
ES2635564T3 (es) Profármaco de tenofovir y usos farmacéuticos del mismo
ES2999323T3 (en) Tlr8 agonist
ES2847051T3 (es) Compuestos de pirrolopirimidina útiles como inhibidores de JAK
ES2701098T3 (es) Derivados de acilaminopirimidina para el tratamiento de infecciones víricas y otras enfermedades
CN101304748A (zh) Tlr激动剂
JP2019527202A (ja) 免疫調節化合物
PT96321B (pt) Processo para a preparacao de nucleosidos de purina
US9517993B2 (en) Antagonists of the toll-like receptor 1/2 complex
CN114206338A (zh) 作为pd-l1抑制剂的二氢化茚类
US12071435B2 (en) TLR8 agonist
CN109096219B (zh) 一种新型抗pd-l1化合物、其应用及含其的组合物
WO2019197598A1 (en) Tlr7 and / or tlr8 agonists
RU2800877C2 (ru) Агонист tlr8
WO2019102054A1 (es) Análogos no glicosídicos de alfa-galactosilceramida como activadores de células nkt
WO2023211940A1 (en) Sting agonists, formulations, and uses thereof
US20250281491A1 (en) Dual functioning immune modulating compounds, formulations, and uses thereof
US12516057B2 (en) Crystalline form of TLR8 agonist
HK1126114A (en) Tlr agonists